Second quarter and first half performance reflected strong B2B revenue growth
Continued improvement in B2C operating performance and profitability
Lowest quarterly operating expense run-rate in the last four quarters
NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Talkspace, Inc. (Nasdaq: TALK), a leading virtual behavioral healthcare company, today reported 2022 second quarter and first half results as summarized below. All financial results refer to 2022 second quarter or first half and the related prior-year period unless otherwise stated.
|Three Months||Six Months|
|Period ended June 30, 2022||Results||Variance from Prior Year %||Results||Variance from Prior Year %|
|(In thousands unless otherwise noted, unaudited)|
|Number of B2B eligible lives (in millions)||77.0||40||%||77.0||40||%|
|Number of completed B2B sessions||96.0||44||%||186.6||54||%|
|Number of B2C active members 1||20.1||(34||)%||20.1||(34||)%|
|Gross margin %||48.7||%||(13.5) pts||49.3||%||(13.7) pts|
|Adjusted EBITDA 2||(16,961||)||(43||)%||(35,372||)||(58||)%|
|Cash and cash equivalents||166,622||(33||)%||166,622||(33||)%|
(1) Reflects active members at the end of the period.
(2) Adjusted EBITDA is a non-GAAP financial measure. For a definition of the measure and a reconciliation to the most directly comparable GAAP measure, see “Reconciliation of Non-GAAP Results to GAAP Results.”
"Second quarter and first half 2022 performance was characterized by continued momentum in business-to-business ("B2B") revenue driven by gains in eligible lives and enterprise clients, offset by a decline in business-to-consumer ("B2C") revenue as we continue to optimize marketing spending," said Chief Financial Officer Jennifer Fulk. “We are focused on executing on our operational priorities along with disciplined resource allocation as we work to enhance our cash flow over time.”
First Half 2022 Key Performance and Financial Metrics
- Revenue grew 3% to $60 million, driven by a 53% growth in B2B revenue, partially offset by a 20% decline in B2C revenue. B2B revenue performance was driven by growth in eligible lives and a greater number of completed B2B sessions. B2C revenue declined, as expected, due to Talkspace's strategic decision to optimize marketing spend.
- Gross profit declined 19% to $30 million, and gross margin declined to 49%, due primarily to the revenue mix shift toward the B2B business in line with our strategy, a greater number of salaried therapists within Talkspace's network, and higher therapist hourly compensation expense.
- Net loss was approximately even compared to the prior period at $(43) million as lower stock-based compensation was offset by higher cost of revenues driven in part by higher therapist-related expenses. Adjusted EBITDA loss was $(35) million, compared to $(22) million in the prior-year period.
Second Quarter 2022 Key Performance and Financial Metrics
- Revenue declined 4% to $30 million as the 47% growth in B2B revenue was more than offset by a 28% decline in B2C revenue.
- Gross profit declined 25% to $15 million, and gross margin declined to 49%.
- Net loss narrowed to $(23) million, compared to a net loss of $(30) million in the prior-year period, driven primarily by lower stock-based compensation. Adjusted EBITDA loss was $(17) million, compared to $(12) million in the prior-year period.
Conference Call, Presentation Slides, and Webcast Details
Visit investors.talkspace.com to view a presentation related to 2022 second quarter and first half results and business outlook and listen to a conference call scheduled to begin at 5:00 p.m. ET on Monday, August 8, 2022. The conference call can also be accessed by dialing (888) 330-2391 for U.S. participants or (240) 789-2702 for international participants (participant code 2348878). A replay will be available shortly after the call’s completion and remain available for approximately 90 days.
Talkspace is a leading virtual behavioral healthcare company enabled by a purpose-built technology platform. As a digital healthcare company, all care is delivered through an easy-to-use and fully encrypted web and mobile platform, consistent with HIPAA and other state regulatory requirements.
Today, the need for care feels more urgent than ever. When seeking treatment, whether it’s psychiatry or adolescent, individual or couples therapy, Talkspace offers treatment options for almost every need. With Talkspace, members can send their dedicated therapists text, video, and voice messages anytime, from anywhere, and engage in live video sessions. As of June 30, 2022, over 3 million people have used Talkspace, and 77 million lives were eligible for Talkspace through insurance and employee assistance programs or other network behavioral health paid benefit programs.
For more information about Talkspace commercial relationships, visit https://business.talkspace.com/. To learn more about online therapy, please visit https://www.talkspace.com/online-therapy/. To learn more about Talkspace Psychiatry, please visit https://www.talkspace.com/psychiatry.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, achieving profitability, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast”, “future”, “intend,” “may,” “might”, “opportunity”, “plan,” “possible”, “potential,” “predict,” “project,” “should,” “strategy”, “strive”, “target,” “will,” or “would”, the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: our history of losses; the rapid evolution of our business and the markets in which we operate; our ability to continue growing at the rates we have historically grown, or at all; the development of the virtual behavioral health market; COVID-19 and its impact on business and economic conditions; a deterioration in general economic conditions as a result of inflation, increased interest rates or otherwise; competition in our industry; and our relationships with affiliated professional entities to provide physician and other professional services. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described under the caption “Risk Factors” in our Annual Report on Form 10-K for the annual period ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on February 25, 2022, and our other documents filed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
Mike Lovell, Senior Director Investor Relations
Consolidated Statements of Operations
|Three Months Ended |
|Variance||Six Months Ended |
|(in thousands, except percentages, share and per share data)|
|Cost of revenues||15,297||11,697||3,600||30.8||30,426||21,511||8,915||41.4|
|Research and development, net||5,576||4,781||795||16.6||10,611||7,745||2,866||37.0|
|Sales and marketing||18,931||26,443||(7,512||)||(28.4||)||40,339||48,694||(8,355||)||(17.2||)|
|General and administrative||8,792||13,710||(4,918||)||(35.9||)||16,802||16,318||484||3.0|
|Total operating expenses||35,615||46,847||(11,232||)||(24.0||)||71,844||76,747||(4,903||)||(6.4||)|
|Financial expense, net||1,865||2,870||(1,005||)||(35.0||)||996||3,043||(2,047||)||(67.3||)|
|Loss before taxes on income||22,933||30,431||7,498||24.6||43,272||43,161||(111||)||(0.3||)|
|Taxes on income||89||10||79||790.0||110||18||92||511.1|
|Net loss per share:|
|Basic and Diluted||$||0.15||$||1.15||$||1.00||87.0||$||0.28||$||2.15||$||1.87||87.0|
|Weighted average number of common shares:|
|Basic and Diluted||155,709,901||26,362,369||154,901,165||20,097,094|
Consolidated Balance Sheets
|June 30, 2022||December 31, 2021|
|Cash and cash equivalents||$||166,622||$||198,256|
|Accounts receivable, net||7,162||5,512|
|Other current assets||3,940||9,562|
|Total current assets||177,724||213,330|
|Property and equipment, net||623||624|
|Intangible assets, net||2,900||3,436|
|Other long-term assets||85||82|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other current liabilities||10,898||12,562|
|Total current liabilities||24,658||27,177|
|Other long-term liabilities||267||86|
|Commitments and contingencies|
|Additional paid-in capital||372,151||363,788|
|Total stockholders’ equity||157,254||192,273|
|Total liabilities and stockholders’ equity||$||187,466||$||223,606|
Consolidated Statements of Cash Flows
|Six Months Ended|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||697||955|
|Amortization of debt issuance cost||—||175|
|Warrant issue costs and change in fair value||1,217||3,043|
|Increase in accounts receivable, net||(1,650||)||(703||)|
|Decrease (increase) in other current assets||5,622||(1,784||)|
|Increase in accounts payable||381||4,833|
|(Decrease) increase in deferred revenues||(1,236||)||2,377|
|Decrease in accrued expenses and other current liabilities||(1,145||)||(213||)|
|Increase in other long-term liabilities||178||—|
|Net cash used in operating activities||(33,111||)||(17,787||)|
|Cash flows from investing activities:|
|Purchase of property and equipment||(160||)||(449||)|
|Net cash used in investing activities||(160||)||(449||)|
|Cash flows from financing activities:|
|(Payments) proceeds from reverse capitalization, net of transaction costs||(645||)||251,325|
|Proceeds from borrowings||—||6,000|
|Repayment of borrowings||—||(6,000||)|
|Payment of debt issuance cost||—||(50||)|
|Proceeds from exercise of stock options||2,349||1,886|
|Payments for employee taxes withheld related to vested stock-based awards||(67||)||—|
|Net cash provided by financing activities||1,637||253,161|
|Net (decrease) increase in cash and cash equivalents||(31,634||)||234,925|
|Cash and cash equivalents at the beginning of the period||198,256||13,248|
|Cash and cash equivalents at the end of the period||$||166,622||$||248,173|
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for this non-GAAP financial measure to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.
We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest and other expenses (income), net, (ii) tax benefit and expense, (iii) depreciation and amortization (iv) stock-based compensation expense and (v) certain non-recurring expenses, where applicable.
Reconciliation of Non-GAAP Results to GAAP Results
|Three Months Ended|
|Six Months Ended|
|Depreciation and amortization||268||493||697||955|
|Financial expense, net (1)||1,865||2,870||996||3,043|
|Taxes on income||89||10||110||18|
|1) For the three and six months ended June 30, 2022, financial expense, net, primarily consisted of $2.1 million and $1.2 million, respectively, in losses resulting from the revaluation of warrant liabilities.|
|For the three months ended June 30, 2021, financial expense, net, primarily consisted of $4.0 million in warrant issuance costs related to the closure of the Business Combination, partially offset by $1.4 million in gains resulting from the revaluation of warrant liabilities. For the six months ended June 30, 2021, financial expense, net, primarily consisted of $4.0 million in warrant issuance costs related to the closure of the Business Combination, partially offset by $1.2 million in gains resulting from the revaluation of warrant liabilities.|